{"id":61984,"date":"2025-10-07T16:03:01","date_gmt":"2025-10-07T14:03:01","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/"},"modified":"2025-10-07T16:03:01","modified_gmt":"2025-10-07T14:03:01","slug":"nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/","title":{"rendered":"nChroma Bio Abstracts Accepted for The Liver Meeting\u00ae 2025 of the American Association for the Study of Liver Diseases (AASLD)"},"content":{"rendered":"
\n

BOSTON–(BUSINESS WIRE)–#AASLD<\/a>–nChroma Bio (\u201cnChroma\u201d), a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the limitations of existing therapies, today announced the acceptance of three abstracts, including a poster of distinction, at the upcoming AASLD Liver Meeting\u00ae, taking place November 7 to 11, 2025, in Washington, D.C.<\/p>\n

<\/a>
<\/a><\/p>\n

\n\u201cAt AASLD, we\u2019re showcasing the rigorous standards applied to the design of our lead chronic hepatitis B program, CRMA-1001, that reflect nChroma Bio\u2019s commitment to delivering an epigenetic silencing solution with the potential for greater efficacy at lower doses,\u201d said Jenny Marlowe, PhD, Chief Development Officer of nChroma.<\/p>\n

\nPoster of Distinction:<\/b><\/p>\n

\nTitle: <\/b>Preclinical pharmacology and safety of CRMA-1001, a novel epigenetic editor for chronic hepatitis B that demonstrates HBV surface antigen loss in animal models via precise HBV DNA methylation
\n
Presenter: <\/b>Sarah Voytek, PhD
\n
Session: <\/b>Hepatitis B
\n
Publication Number:<\/b> 1118
\n
Date & Time:<\/b> November 7, 2025, 8:00 a.m. \u2013 5:00 p.m.<\/p>\n

\nAdditional Poster Presentations:<\/b><\/p>\n

\nTitle:<\/b> Epigenetic editors targeting chronic Hepatitis B achieve HBV surface antigen loss with a single course of treatment in multiple HBV mouse models
\n
Presenter:<\/b> Glen Acosta, PhD
\n
Session: <\/b>Hepatitis B
\n
Publication Number:<\/b> 1262
\n
Date & Time:<\/b> November 7, 2025, 8:00 a.m. \u2013 5:00 p.m.<\/p>\n

\nTitle: <\/b>Establishment of assay limits for differential gene expression and DNA methylation to characterize specificity of epigenetic editing
\n
Presenter:<\/b> Erica Hildebrand, PhD
\n
Session: <\/b>Genomics and Precision Medicine
\n
Publication Number: <\/b>4304
\n
Date & Time:<\/b> November 10, 2025, 8:00 a.m. \u2013 5:00 p.m.<\/p>\n

\nThe abstracts are available on the conference website at https:\/\/www.aasld.org\/sites\/default\/files\/2025-10\/HEP_82_S1-FINAL.pdf<\/a><\/p>\n

\nOur Approach<\/b><\/p>\n

\nLeveraging complementary scientific approaches to pair innovative cargo with target-appropriate in vivo delivery methods, nChroma Bio is taking a disease-first approach to design customized genetic medicines. nChroma\u2019s lead program is a liver-directed, epigenetic silencer in development as a potential functional cure for chronic hepatitis B.<\/p>\n

\nAbout nChroma Bio<\/b><\/p>\n

\nnChroma Bio is a genetic medicines company committed to addressing the limitations of existing therapies through a disease-first approach. By combining programmable in vivo delivery and gene-regulating technologies, nChroma is designing optimal solutions to deliver precise, potent and durable treatments for patients with high unmet needs. nChroma\u2019s lead candidate, CRMA-1001, is a near clinical-stage, liver-directed epigenetic therapy in development as a potential functional cure for chronic hepatitis B. Guided by a world-class team at the forefront of genetic medicine, founded by renowned pioneers in the field, and supported by top-tier investors, nChroma is redefining targeted in vivo genetic medicine with the initial goal of treating diseases affecting the liver, blood, and central nervous system. For more information, visit nChromaBio.com<\/a> and follow us on LinkedIn<\/a> and X<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nMedia Contact
\n
\n<\/b>
Michelle Linn
\n
Linnden Communications
\n
michelle@linndencom.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

BOSTON–(BUSINESS WIRE)–#AASLD–nChroma Bio (\u201cnChroma\u201d), a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the limitations of existing therapies, today announced the acceptance of three abstracts, including a poster of distinction, at the upcoming AASLD Liver Meeting\u00ae, taking place November 7 to 11, 2025, in Washington, D.C. \u201cAt AASLD, we\u2019re showcasing the … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61984","6":"format-standard","7":"category-industry"},"yoast_head":"\nnChroma Bio Abstracts Accepted for The Liver Meeting\u00ae 2025 of the American Association for the Study of Liver Diseases (AASLD) - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"nChroma Bio Abstracts Accepted for The Liver Meeting\u00ae 2025 of the American Association for the Study of Liver Diseases (AASLD) - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON–(BUSINESS WIRE)–#AASLD–nChroma Bio (\u201cnChroma\u201d), a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the limitations of existing therapies, today announced the acceptance of three abstracts, including a poster of distinction, at the upcoming AASLD Liver Meeting\u00ae, taking place November 7 to 11, 2025, in Washington, D.C. \u201cAt AASLD, we\u2019re showcasing the ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-07T14:03:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20251007878830\/en\/2601263\/22\/nChroma-Primary-Logo-4x.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"nChroma Bio Abstracts Accepted for The Liver Meeting\u00ae 2025 of the American Association for the Study of Liver Diseases (AASLD)\",\"datePublished\":\"2025-10-07T14:03:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\\\/\"},\"wordCount\":459,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251007878830\\\/en\\\/2601263\\\/22\\\/nChroma-Primary-Logo-4x.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\\\/\",\"name\":\"nChroma Bio Abstracts Accepted for The Liver Meeting\u00ae 2025 of the American Association for the Study of Liver Diseases (AASLD) - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251007878830\\\/en\\\/2601263\\\/22\\\/nChroma-Primary-Logo-4x.jpg\",\"datePublished\":\"2025-10-07T14:03:01+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251007878830\\\/en\\\/2601263\\\/22\\\/nChroma-Primary-Logo-4x.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20251007878830\\\/en\\\/2601263\\\/22\\\/nChroma-Primary-Logo-4x.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"nChroma Bio Abstracts Accepted for The Liver Meeting\u00ae 2025 of the American Association for the Study of Liver Diseases (AASLD)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"nChroma Bio Abstracts Accepted for The Liver Meeting\u00ae 2025 of the American Association for the Study of Liver Diseases (AASLD) - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/","og_locale":"en_US","og_type":"article","og_title":"nChroma Bio Abstracts Accepted for The Liver Meeting\u00ae 2025 of the American Association for the Study of Liver Diseases (AASLD) - Pharma Trend","og_description":"BOSTON–(BUSINESS WIRE)–#AASLD–nChroma Bio (\u201cnChroma\u201d), a genetic medicines company advancing in vivo delivery of innovative cargoes to overcome the limitations of existing therapies, today announced the acceptance of three abstracts, including a poster of distinction, at the upcoming AASLD Liver Meeting\u00ae, taking place November 7 to 11, 2025, in Washington, D.C. \u201cAt AASLD, we\u2019re showcasing the ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/","og_site_name":"Pharma Trend","article_published_time":"2025-10-07T14:03:01+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20251007878830\/en\/2601263\/22\/nChroma-Primary-Logo-4x.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"nChroma Bio Abstracts Accepted for The Liver Meeting\u00ae 2025 of the American Association for the Study of Liver Diseases (AASLD)","datePublished":"2025-10-07T14:03:01+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/"},"wordCount":459,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251007878830\/en\/2601263\/22\/nChroma-Primary-Logo-4x.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/","url":"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/","name":"nChroma Bio Abstracts Accepted for The Liver Meeting\u00ae 2025 of the American Association for the Study of Liver Diseases (AASLD) - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20251007878830\/en\/2601263\/22\/nChroma-Primary-Logo-4x.jpg","datePublished":"2025-10-07T14:03:01+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20251007878830\/en\/2601263\/22\/nChroma-Primary-Logo-4x.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20251007878830\/en\/2601263\/22\/nChroma-Primary-Logo-4x.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/nchroma-bio-abstracts-accepted-for-the-liver-meeting-2025-of-the-american-association-for-the-study-of-liver-diseases-aasld\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"nChroma Bio Abstracts Accepted for The Liver Meeting\u00ae 2025 of the American Association for the Study of Liver Diseases (AASLD)"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61984","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61984"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61984\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61984"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61984"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61984"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}